Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (3959)	5/12/1999 9:17:00 PM
From: PAFOOFNICK	Read Replies (1) \| Respond to of 4891

It brings a little joy to a very bad day. Gooooooooooooo advr

To: BARRY ALLEN who wrote (3959)	5/13/1999 10:09:00 AM
From: JustMy2Cents	Read Replies (2) \| Respond to of 4891

Advanced Viral Research Corp. Receives U.S. Patent Entitled ''Treatment of Basal Cell Carcinoma With Product R, a Peptide-Nucleic Acid Preparation'' Business Wire - May 13, 1999 09:32 YONKERS, N.Y.--(BW HealthWire)--May 13, 1999--Advanced Viral Research Corp. (OTC BB:ADVR) announced the award of U.S. Patent No. 5,902,786 in May 1999 titled, "Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation." "Basal cell carcinoma is a common skin cancer often appearing on the face. The award of another patent reflects the breadth of potential applications of our peptide-nucleic acid type drugs," commented Dr. Shalom Z. Hirschman, president and CEO of Advanced Viral Research Corp. NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Reticulose is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. CONTACT: Advanced Viral Research Corp., Hallandale, Fla. Mark Amster, 954/458-7636